What's New In the Consumer Tech World Last Week? News That You Should Know (June 9-June 15, 2024)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 16 2024
0mins
Should l Buy DXCM?
Source: Benzinga
- Mark Cuban's View on AI: Mark Cuban believes that U.S. government and investor efforts to regulate AI may give Chinese companies an advantage in the field.
- Data Breaches Diplomatic Tensions: Data breaches at a $20 billion internet company co-owned by SoftBank Corp and Naver are causing diplomatic tensions between Japan and South Korea.
- Impact of Gossip App Fizz: The launch of a gossip app, Fizz, at a Vermont high school has led to bullying and controversy, raising concerns about social media's impact on teen mental health.
- Tech Collaborations: Vrio Corporation partners with Amazon's Project Kuiper for satellite broadband, while Apple integrates Google Gemini AI model into its Apple Intelligence feature set.
- Elon Musk Updates: Elon Musk ends speculation about a Tesla smartphone, criticizes Apple's partnership with OpenAI, and withdraws his lawsuit against OpenAI.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DXCM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DXCM
Wall Street analysts forecast DXCM stock price to rise
16 Analyst Rating
13 Buy
2 Hold
1 Sell
Strong Buy
Current: 66.600
Low
68.00
Averages
82.54
High
100.00
Current: 66.600
Low
68.00
Averages
82.54
High
100.00
About DXCM
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DEXCOM STOCK RISES 0.4% FOLLOWING EVERCORE ISI UPGRADE TO OUTPERFORM FROM IN LINE
Stock Performance: Dexcom shares increased by 0.4% following a positive earnings report.
Earnings Report Impact: The rise in stock price was attributed to a strong performance from the company's core business.
See More
MIG Capital Reduces Stake in Sotera Health by $37 Million
- Stake Reduction Details: On February 17, 2026, MIG Capital disclosed a reduction of 2,262,292 shares in Sotera Health (NASDAQ:SHC), with an estimated transaction value of $37.41 million, indicating a potential decrease in confidence in the company's future performance.
- Position Value Decline: By the end of Q4 2025, the total position value for Sotera Health declined by $31.83 million, reflecting the impact of market fluctuations and trading activities on MIG Capital's asset management, which may affect investor sentiment regarding the stock.
- Sustained Profitability: Despite the reduction, Sotera Health continues to demonstrate strong profitability, with a 5.7% increase in sales to $1.16 billion in 2025 and net income nearly doubling to $78 million, underscoring its solid market position in the medical device and food safety sectors.
- Future Growth Outlook: The company projects revenue growth of 5% to 6.5% and adjusted EBITDA growth of 5.5% to 7% for 2026, suggesting that despite MIG Capital's stake reduction, Sotera Health still possesses significant growth potential, which may attract long-term investor interest.
See More
Adobe CEO Resignation Triggers Stock Decline
- Adobe CEO Transition: Adobe's CEO Shantanu Narayen announced his resignation after a successor is named, causing shares to tumble over 5%, despite the company beating first-quarter earnings expectations, indicating market concerns over leadership changes.
- Fertilizer Stocks Retreat: Fertilizer companies' shares fell back due to ongoing disruptions in the Strait of Hormuz, with Intrepid Potash down about 8% and both Mosaic and CF Industries dropping around 4%, reflecting market sensitivity to raw material price fluctuations.
- Ulta Beauty Earnings Miss: Ulta Beauty reported fourth-quarter earnings of $8.01 per share, falling short of the $8.03 expected by analysts, leading to a 12% drop in stock price, despite revenue of $3.9 billion exceeding expectations, highlighting pressures on profitability.
- Once Upon A Farm Performance Decline: Once Upon A Farm reported its first earnings since going public, guiding for 2026 adjusted EBITDA of $2 million to $4 million, significantly lower than $6.6 million in Q4 2025, resulting in an 8% stock drop and raising concerns about future growth prospects.
See More
Dexcom G7 Enhances Diabetes Management and Health Outcomes
- Long-Term Benefits: New registry study data indicates that long-term use of Dexcom G7 significantly aids weight management and lowers A1C levels for Type 2 diabetes patients not on insulin therapy, reinforcing the need to broaden CGM access beyond insulin-treated populations, thereby enhancing overall patient health outcomes.
- Clinical Evidence Showcase: Dexcom will present multiple clinical and real-world evidence at the 2026 ATTD conference in Barcelona, demonstrating the health benefits of its CGM technology for all diabetes types, further solidifying its leadership position in diabetes management.
- Commitment to Education and Innovation: Dexcom is launching the Dexcom Academy education platform aimed at enhancing healthcare professionals' CGM support capabilities through a structured training framework, with plans for rollout in several countries, thereby increasing the professionalism of global diabetes care.
- Product Roadmap: At the ATTD conference, Dexcom will unveil upcoming product features, including Dexcom G7 and Dexcom ONE+, showcasing its ongoing innovation in diabetes management and health, further driving CGM education and product advancements.
See More
Dexcom CGM Enhances Long-Term Health for Diabetes Patients
- Long-Term Health Improvement: New registry study data indicates that long-term use of Dexcom G7 significantly lowers A1C levels and aids weight management for non-insulin-treated Type 2 diabetes patients, reinforcing the need to broaden CGM access to enhance overall health outcomes for diabetes patients.
- Reduced Hospitalization Rates: The use of Dexcom CGM is associated with significant reductions in diabetic ketoacidosis (DKA)-related hospitalizations and emergency room visits, demonstrating the effectiveness of real-time glucose monitoring and alert systems in both children and adults, thereby solidifying Dexcom's critical role in diabetes management.
- Education and Training Framework: At the upcoming ATTD conference, Dexcom will introduce the first consensus-based CGM competency framework aimed at providing healthcare professionals with a clear training structure, which will enhance the quality and consistency of CGM support and advance industry education.
- Commitment to Product Innovation: Dexcom will showcase its product roadmap at ATTD, emphasizing its ongoing innovation in diabetes care and health sectors, particularly with the upcoming Dexcom G7 and the Dexcom Academy education platform, aimed at raising the standard of diabetes management globally.
See More
Intuitive Surgical and DexCom: Future Prospects Analysis
- Challenges for Intuitive Surgical: Intuitive Surgical has faced tariffs and competition from Medtronic's new Hugo system, resulting in a 13% stock price decline over the past year; however, it is expected to benefit from the growing surgical demand due to an aging population over the next decade, maintaining its market leadership.
- Market Potential: By 2034, the U.S. population aged 65 and older is projected to exceed those aged 18 and under, which will drive demand for Intuitive Surgical's da Vinci system, allowing for revenue and earnings growth despite competitive pressures due to its high switching costs and innovative capabilities.
- DexCom's Market Opportunities: DexCom's leadership in the CGM market remains intact despite last year's minor product recalls, with potential to expand its market share by targeting over 9 million insured diabetes patients who are not currently using CGM technology.
- New Product Development: DexCom's new product Stelo has attracted over 500,000 users in the U.S., targeting the large market of over 40% of the population with prediabetes, indicating significant growth potential in the non-diabetic patient segment, which is expected to drive future company growth.
See More
DEXCOM STOCK RISES 0.4% FOLLOWING EVERCORE ISI UPGRADE TO OUTPERFORM FROM IN LINE
Stock Performance: Dexcom shares increased by 0.4% following a positive earnings report.
Earnings Report Impact: The rise in stock price was attributed to a strong performance from the company's core business.
See More
MIG Capital Reduces Stake in Sotera Health by $37 Million
- Stake Reduction Details: On February 17, 2026, MIG Capital disclosed a reduction of 2,262,292 shares in Sotera Health (NASDAQ:SHC), with an estimated transaction value of $37.41 million, indicating a potential decrease in confidence in the company's future performance.
- Position Value Decline: By the end of Q4 2025, the total position value for Sotera Health declined by $31.83 million, reflecting the impact of market fluctuations and trading activities on MIG Capital's asset management, which may affect investor sentiment regarding the stock.
- Sustained Profitability: Despite the reduction, Sotera Health continues to demonstrate strong profitability, with a 5.7% increase in sales to $1.16 billion in 2025 and net income nearly doubling to $78 million, underscoring its solid market position in the medical device and food safety sectors.
- Future Growth Outlook: The company projects revenue growth of 5% to 6.5% and adjusted EBITDA growth of 5.5% to 7% for 2026, suggesting that despite MIG Capital's stake reduction, Sotera Health still possesses significant growth potential, which may attract long-term investor interest.
See More
Adobe CEO Resignation Triggers Stock Decline
- Adobe CEO Transition: Adobe's CEO Shantanu Narayen announced his resignation after a successor is named, causing shares to tumble over 5%, despite the company beating first-quarter earnings expectations, indicating market concerns over leadership changes.
- Fertilizer Stocks Retreat: Fertilizer companies' shares fell back due to ongoing disruptions in the Strait of Hormuz, with Intrepid Potash down about 8% and both Mosaic and CF Industries dropping around 4%, reflecting market sensitivity to raw material price fluctuations.
- Ulta Beauty Earnings Miss: Ulta Beauty reported fourth-quarter earnings of $8.01 per share, falling short of the $8.03 expected by analysts, leading to a 12% drop in stock price, despite revenue of $3.9 billion exceeding expectations, highlighting pressures on profitability.
- Once Upon A Farm Performance Decline: Once Upon A Farm reported its first earnings since going public, guiding for 2026 adjusted EBITDA of $2 million to $4 million, significantly lower than $6.6 million in Q4 2025, resulting in an 8% stock drop and raising concerns about future growth prospects.
See More
Dexcom G7 Enhances Diabetes Management and Health Outcomes
- Long-Term Benefits: New registry study data indicates that long-term use of Dexcom G7 significantly aids weight management and lowers A1C levels for Type 2 diabetes patients not on insulin therapy, reinforcing the need to broaden CGM access beyond insulin-treated populations, thereby enhancing overall patient health outcomes.
- Clinical Evidence Showcase: Dexcom will present multiple clinical and real-world evidence at the 2026 ATTD conference in Barcelona, demonstrating the health benefits of its CGM technology for all diabetes types, further solidifying its leadership position in diabetes management.
- Commitment to Education and Innovation: Dexcom is launching the Dexcom Academy education platform aimed at enhancing healthcare professionals' CGM support capabilities through a structured training framework, with plans for rollout in several countries, thereby increasing the professionalism of global diabetes care.
- Product Roadmap: At the ATTD conference, Dexcom will unveil upcoming product features, including Dexcom G7 and Dexcom ONE+, showcasing its ongoing innovation in diabetes management and health, further driving CGM education and product advancements.
See More
Dexcom CGM Enhances Long-Term Health for Diabetes Patients
- Long-Term Health Improvement: New registry study data indicates that long-term use of Dexcom G7 significantly lowers A1C levels and aids weight management for non-insulin-treated Type 2 diabetes patients, reinforcing the need to broaden CGM access to enhance overall health outcomes for diabetes patients.
- Reduced Hospitalization Rates: The use of Dexcom CGM is associated with significant reductions in diabetic ketoacidosis (DKA)-related hospitalizations and emergency room visits, demonstrating the effectiveness of real-time glucose monitoring and alert systems in both children and adults, thereby solidifying Dexcom's critical role in diabetes management.
- Education and Training Framework: At the upcoming ATTD conference, Dexcom will introduce the first consensus-based CGM competency framework aimed at providing healthcare professionals with a clear training structure, which will enhance the quality and consistency of CGM support and advance industry education.
- Commitment to Product Innovation: Dexcom will showcase its product roadmap at ATTD, emphasizing its ongoing innovation in diabetes care and health sectors, particularly with the upcoming Dexcom G7 and the Dexcom Academy education platform, aimed at raising the standard of diabetes management globally.
See More
Intuitive Surgical and DexCom: Future Prospects Analysis
- Challenges for Intuitive Surgical: Intuitive Surgical has faced tariffs and competition from Medtronic's new Hugo system, resulting in a 13% stock price decline over the past year; however, it is expected to benefit from the growing surgical demand due to an aging population over the next decade, maintaining its market leadership.
- Market Potential: By 2034, the U.S. population aged 65 and older is projected to exceed those aged 18 and under, which will drive demand for Intuitive Surgical's da Vinci system, allowing for revenue and earnings growth despite competitive pressures due to its high switching costs and innovative capabilities.
- DexCom's Market Opportunities: DexCom's leadership in the CGM market remains intact despite last year's minor product recalls, with potential to expand its market share by targeting over 9 million insured diabetes patients who are not currently using CGM technology.
- New Product Development: DexCom's new product Stelo has attracted over 500,000 users in the U.S., targeting the large market of over 40% of the population with prediabetes, indicating significant growth potential in the non-diabetic patient segment, which is expected to drive future company growth.
See More
